Feasibility, Reliability, and Satisfaction of CEA Using Home Based (automated) Capillary Blood Sampling
Launched by ERASMUS MEDICAL CENTER · Dec 2, 2022
Trial Information
Current as of January 16, 2025
Completed
Keywords
ClinConnect Summary
The follow-up of patients after colorectal cancer surgery mainly consists of blood CEA assessments. These blood assessments could be done at home and could be beneficial in terms of patients' well-being and societal cost-effectiveness. Capillary blood sampling can be an alternative to venipuncture in home based or decentralized surveillance as it can be performed by the patient themselves. Before home based capillary sampling can be implemented, feasibility, reliability, and satisfaction for serum CEA measurements has to be determined.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Arm A: subjects with known elevated serum CEA
- • Age ≥ 21 years
- • Histologically confirmed (metastatic) colorectal adenocarcinoma
- • Serum CEA ≥ 10 μg/L within the last 2 months determined using venipuncture blood sampling
- • Arm B: subjects currently undergoing colorectal cancer related follow-up
- • Age ≥ 21 years
- • Histologically confirmed (metastatic) colorectal adenocarcinoma
- • Currently undergoing in-hospital follow-up with at least two more scheduled serum CEA assessments 3-6 months apart
- • Arm C: volunteers
- • Age ≥ 21 years
- • No known history of colorectal adenocarcinoma
- • No known history of elevated serum CEA ≥ 5 μg/L
- Exclusion Criteria:
- • Illiteracy and/or insufficient proficiency of the Dutch language
- • Severe or complete loss of sensory and or motor function of one or both arms and or hands
- • Known medical history of superficial or deep skin infection after venipuncture or intravenous line that required antibiotic treatment and or hospital admittance
- • Known medical history of immunodeficiency or current use of medical immunosuppressants
- • Known medical history of blood-borne diseases such as but not limited to the human immunodeficiency virus, hepatitis and viral hemorrhagic fever
Trial Officials
Dirk J. Grünhagen, MD, PhD
Principal Investigator
Erasmus Medical Center
About Erasmus Medical Center
Erasmus Medical Center, located in Rotterdam, Netherlands, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution within the Erasmus University Rotterdam, the center integrates cutting-edge scientific inquiry with comprehensive patient care, focusing on a wide range of medical specialties. With a strong emphasis on multidisciplinary collaboration, Erasmus Medical Center aims to translate research findings into tangible clinical applications, enhancing treatment options and improving patient outcomes. The institution is dedicated to conducting ethical and rigorous clinical trials that contribute to the global body of medical knowledge and foster advancements in personalized medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, , Netherlands
Rotterdam, Zuid Holland, Netherlands
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials